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Rockefeller University, New York, NY, USAAbstractThe aim of the present study was to determine the prevalence and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal
carriage among patients and healthcare workers in Angola (ANG), São Tomé and Príncipe (STP), Cape Verde (CV) and East Timor (ET), and
to characterize the antimicrobial susceptibility, virulence content and population structure of all S. aureus. Despite the importance of MRSA as
a major human pathogen, data from these former Portuguese colonies in Africa and Asia are scarce. A total of 2065 nasal swabs recovered
between 2010–14 were included in the study. Antimicrobial susceptibility testing and molecular characterization of S. aureus showed: (i) a
very high MRSA prevalence in ANG (61.6%), moderate in STP (25.5%), low in CV (5.6%) and null in ET; (ii) a high prevalence of
Panton–Valentine leukocidin in STP (36.8%), ET (29.2%) and CV (28.3%) contrasting with ANG (7.9%); (iii) ST5-SCCmecIVa, ST8-IV/V
and ST5-VI were the major MRSA clones in ANG (65.2%), STP (44.8%) and CV (50%), respectively; (iv) a high resistance to
trimethoprim-sulfamethoxazole in ANG (66.5%) and STP (50.9%), to rifampin in ANG (77.3%), and to tetracycline in STP (26.3%) and ET
(20.8%); (v) three major methicillin-susceptible S. aureus clones (ST15, ST508, ST152) were present in all four countries. Age <18 years
(OR 2.03, 95% CI 1.24–3.31), previous surgery (OR 2.45, 95% CI 1.24–4.83), no smoking (OR 4.04, 95% CI 1.05–15.50), and longer
hospitalization (OR 2.53, 95% CI 1.49–4.28) were risk factors for MRSA carriage. This study provided the ﬁrst comprehensive overview
on MRSA in former Portuguese colonies in Africa and Asia, missing data in the world map.
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E-mail: msousa@esscvp.euIntroductionMethicillin-resistant Staphylococcus aureus (MRSA) is a major
threat to public health not only in the developed world, but in
developing regions as well where human immunodeﬁciencyMicrobiol Infect 2015; 21: 842.e1–842.e10
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.05.010virus (HIV)/AIDS, malaria, malnutrition, crowded living condi-
tions, high temperatures and humidity additionally contribute to
the increased risk of bacterial infections [1,2]. However, in
many developing regions, research protocols do not include
major bacterial pathogens such as MRSA and funding for health
and research is mainly directed to HIV/AIDS, malaria and
tuberculosis programmes, namely in Sub-Saharan Africa [3]. In
many developing and low-income countries there is a lack of
microbiological diagnostic facilities and patients with signs of
infection are often treated empirically; as a result, the assess-
ment of MRSA rates and antimicrobial resistance proﬁles is of
major importance.ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Conceição et al. Staphylococcus aureus in former Portuguese colonies 842.e2During the last 10 years Portugal has been reporting one of
the highest rates of MRSA in Europe (around 50%) [4]. How-
ever, S. aureus epidemiological surveillance studies in former
Portuguese colonies in Africa and Asia, with close demographic
relationships with Portugal, remain scarce. Data from Angola
and São Tomé and Príncipe are limited to single studies from
our group [5,6]. The unique S. aureus surveillance study con-
ducted in Cape Verde included isolates from 1997 and at that
time MRSA was not detected [7,8]. In Mozambique a recent
study assessed exclusively the antimicrobial susceptibility of
S. aureus and the MRSA prevalence in a single hospital [9].
Studies from East Timor are inexistent so far. Moreover, no
single work provided an overview on MRSA in former Portu-
guese colonies in Africa and Asia, which is essential to help
deﬁning local and global public health priorities, and to
contribute for the global picture of MRSA epidemiology.
The aim of the present study was to assess rates of MRSA
nasal carriage among patients and healthcare workers (HCW)
in Angola, São Tomé and Príncipe, Cape Verde and East Timor,
to determine risk factors associated with MRSA colonization,
and to characterize the antimicrobial susceptibility, virulence
content and population structure of S. aureus.Materials and methodsHospitals
Ten hospitals participated in the surveillance study (see Sup-
porting information, Table S1): (i) Angola: Hospital Pediátrico
David Bernardino (HPDB), Hospital Américo Boavida (HAB),
Clínica Sagrada Esperança (CSE), Hospital Maria Pia (HMP) and
Clínica Girassol (CG); (ii) São Tomé and Príncipe: Hospital
Ayres de Menezes (HAM); (iii) Cape Verde: Hospital Agostinho
Neto (HAN) and Hospital Baptista de Sousa (HBS); and (iv) East
Timor: Hospital Guido Valadares (HGV) and Clínica do Bairro
Pité (CBP).
Bacterial isolates
From November 2010 to June 2014, a total of 2065 individuals
(1267 inpatients and 798 HCW) from Angola (n = 893), São
Tomé and Príncipe (n = 490), Cape Verde (n = 515) and East
Timor (n = 167) were screened for S. aureus nasal carriage (see
Supporting information, Table S1).
Sampling included all patients admitted in the main services
where the risk for S. aureus infection is usually high (intensive
care and burn units, medicine, surgery, paediatrics and ortho-
paedics) and all HCW from the same wards, active at the time
of sampling. HCW included doctors (n = 144), nurses
(n = 395), nurse-aids (n = 147), cleaners (n = 54) and techni-
cians (n = 53).Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfThe protocol was approved by the institutional review
boards. An informed consent was obtained from each partici-
pant, or from the guardians in the case of children, after a verbal
presentation of the purpose, method and design of the study. A
brief questionnaire was administered verbally by the partici-
pating author (MAS) to inpatients, guardians in the case of
children, and HCW to collect data concerning their living
conditions at home (number of household members, running
water facilities and contact with animals) and smoking behav-
iour. Demographic data as well as admission date, clinical
diagnosis, previous surgery and antibiotic usage history were
registered after on-site consultation of the clinical records.
Exclusion criteria included inpatients admitted for less than
48 h, individuals with inaccessible nares due to the presence of
medical devices, children being breastfed at the time of
screening, and individuals who refused to participate in the
study.
Sampling and S. aureus identiﬁcation
Sampling was performed by a trained nurse and participating
author during a 2- or 3-day period in each hospital. Cultures
were obtained by rotating a sterile cotton swab into both
anterior nares several times before returning the swab to the
transport tube, which contained Stuart’s medium. The swabs
were transported within 10 days at room temperature to the
Laboratory of Molecular Genetics, Instituto de Tecnologia
Química e Biológica in Portugal, where they were inoculated on
Tryptic Soy Agar (Becton Dickinson, Franklin Lakes, New Jersey,
USA) and on a selective chromogenic medium Chromagar Staph
aureus (ChromAgar; Paris, France). All presumptive S. aureus
colonies were tested for coagulase by latex agglutination test
Staphaurex (Remel, Lenexa, Kansas, USA) or by agglutination of
rabbit plasma in tubes (Becton Dickinson) in the case of previ-
ously ambiguous results. The S. aureus species was conﬁrmed by
PCR ampliﬁcation of the nuc [10] or spa [11] genes.
Antimicrobial susceptibility testing and conﬁrmative
identiﬁcation of MRSA
Antimicrobial susceptibility testing was performed on all iso-
lates by the disc diffusion method for a panel of 16 antibiotics:
penicillin, cefoxitin, erythromycin, gentamicin, clindamycin,
trimethoprim-sulfamethoxazole, chloramphenicol, ciproﬂoxa-
cin, rifampin, tetracycline, fusidic acid, mupirocin, teicoplanin,
vancomycin, linezolid and quinupristin-dalfopristin. Standard
published CLSI breakpoints were used for interpretation,
except for fusidic acid and mupirocin for which breakpoints
from the European Committee on Antimicrobial Susceptibility
Testing and the British Society for Antimicrobial Chemotherapy
(http://bsac.org.uk/susceptibility/) guidelines were respectively
applied. Strain S. aureus ATCC25923 was used as qualityectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 842.e1–842.e10
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on all S. aureus isolates by PCR ampliﬁcation of the mecA gene
[12]. Vancomycin MICs were determined for MRSA isolates
using E-test strips, according to the manufacturer’s instructions
(Biomérieux, Marcy l’Etoile, France).
Molecular typing and virulence determinants
Four typing methods—pulsed-ﬁeld gel electrophoresis (PFGE),
spa typing, multilocus sequence typing (MLST) and staphylo-
coccal cassette chromosome mec (SCCmec) typing—were
used in the present study. PFGE was performed on all S. aureus
isolates as described by Chung et al. [13] and the resulting band
proﬁles were analysed by visual inspection, followed by auto-
mated analysis with the BIONUMERICS software version 6.6
(Applied Maths, Sint-Martens-Latem, Belgium) as previously
described [14]. spa typing was performed on at least one
representative of each PFGE subtype, and spa types were
assigned through the Ridom web server (http://spaserver.
ridom.de) [11]. MLST was performed on representative iso-
lates of each PFGE type [15] and the allelic proﬁles and
sequence types (ST) were deﬁned using the MLST online
database (http://www.mlst.net). SCCmec was characterized by
multiplex PCR [16] in all MRSA isolates and SCCmec type IV
isolates were further subtyped [17]. SCCmec type VII was
identiﬁed by PCR ampliﬁcation of mec complex C1 and ccrC
[18].
Detection of exotoxins, arginine catabolic mobile
element and agr type
The presence of 11 speciﬁc staphylococcal exotoxin genes,
including three leukocidins (lukS-lukF (Panton–Valentine leu-
kocidin (PVL) determinant), lukD-lukE, lukM), three haemolysins
(hlb, hlg, hlgv) and ﬁve super-antigenic toxins (eta, etb, etd, sel,
sep) were determined by PCR for all S. aureus isolates [19].
MRSA isolates belonging to ST8 were screened for the pres-
ence of the arginine catabolic mobile element by PCR ampliﬁ-
cation of arcA and opp3 [20,21]. Subtypes of the accessory gene
regulator (agr I– IV) were determined for the entire collection
by multiplex PCR [22].
Statistical analysis
Risk factors were assessed using SPSS software, version 21.0.
Categorical variables were summarized using the frequency
and percentage. The chi-squared test was used to identify
variables associated with MRSA carriage. Odds ratio (OR) was
calculated for all variables found to be statistically signiﬁcant at
a level of signiﬁcance of 0.05. All signiﬁcant variables detected
in the univariate analyses were introduced into the ﬁnalClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectmultivariate model. Variables were considered to be signiﬁ-
cantly associated to MRSA carriage if the 95% CI of the OR
did not contain 1.ResultsPopulation description
A total of 2065 individuals (61.4% inpatients and 38.6% HCW)
participated in the study. The characteristics of the population
are displayed in the Supplementary material (Table S2). Brieﬂy,
the demographic data showed that 55.6% of the participants
were female and 73.5% were adults. Most of the individuals
(67.0%) were not previously submitted to surgery and 66.4%
were under current or previous antibiotherapy (mainly β-lac-
tams). In addition, the majority (93.7%) were non-smokers, had
contact with animals (62.0%—mainly with chicken, cats and
pigs), had no running water at home (54.1%) and lived with
more than three householders (77.0%).
Concerning exclusively the patients, 46.5% were admitted to
the hospital the week preceding sampling (between 48 h and 8
days), and the main reasons for admission were orthopaedic
(16.9%), respiratory (10.7%) and gastrointestinal (9.8%).
MRSA prevalence
Among the 2065 participants who underwent nasal screening,
424 were S. aureus carriers (20.5%). Although we found a global
MRSA prevalence of 34.8% among S. aureus carriers (148 out of
424 S. aureus) there were signiﬁcant inter-country variations:
the prevalence was very high in Angola (61.6%; 114/185),
moderate in São Tomé and Príncipe (25.5%; 28/110), low in
Cape Verde (5.6%; 6/107) and null in East Timor (0/22) (see
Supplementary material, Table S1).
Considering the ten hospitals individually, we did not detect
MRSA among nasal samples in the hospital on the island of São
Vicente in Cape Verde (HBS) nor in the two hospitals in East
Timor (see Supplementary material, Table S1). In Angola, with
the exception of hospital CG where the single S. aureus isolate
recovered was methicillin resistant, the MRSA prevalence was
higher in the largest public hospital (HMP, 70.6%) and lower in
the smallest private hospital (CSE, 40.6%). Interestingly, in this
hospital the MRSA prevalence was signiﬁcantly higher among
HCW (76.9%) compared with patients; whereas usually (and as
happened in Angola and São Tomé and Príncipe) higher MRSA
rates were found among patients (74.6% and 71.4%, respec-
tively) (see Supplementary material, Table S1). Among a total of
40 HCW that were MRSA carriers, the overwhelming majority
(32; 80%) were nurses (23; 57.5%) and doctors (9; 22.5%).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 842.e1–842.e10
(a)
(b)
FIG. 1. Antimicrobial resistance in Angola (ANG), São Tomé and Príncipe (STP), Cape Verde (CV) and East-Timor (ET) among (a) Staphylococcus
aureus isolates and among (b) methicillin-resistant Staphylococcus aureus (MRSA). FOX, cefoxitin; PEN, penicillin; RIF, rifampin; CLI, clindamycin; ERY,
erythromycin; TET, tetracycline; CIP, ciproﬂoxacin; GEN, gentamicin; SXT, trimethoprim-sulfamethoxazole; CHL, chloramphenicol; FUS, fusidic acid;
MUP, mupirocin; QD, quinupristin-dalfopristin; LZD, linezolid; TEI, teicoplanin; VAN, vancomycin.
CMI Conceição et al. Staphylococcus aureus in former Portuguese colonies 842.e4As 30 individuals were co-colonized with two S. aureus
isolates (differing by PFGE type or subtype or an MRSA/
methicillin-susceptible S. aureus (MSSA) pair), the whole
collection comprised a total of 454 S. aureus (162 MRSA and
292 MSSA) that were subsequently characterized.
Risk factors for MRSA carriage
The variables signiﬁcantly associated with MRSA carriage in
univariate analysis were the following: being a patient (p 0.001),
age <18 years (p < 0.001), surgery in the previous 6 months (p
0.001), current or previous antibiotherapy (p < 0.001), being a
non-smoker (p 0.022), having no contact with animals (p 0.001),
no running water at home (p 0.020) and being hospitalized for
more than 30 days (p 0.001) (see Supplementary material,
Table S3).
After multivariate analysis, being <18 years old (OR 2.03,
95% CI 1.24–3.31), having been submitted to a surgery in theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infprevious 6 months (OR 2.45, 95% CI 1.24–4.83), being a non-
smoker (OR 4.04, 95% CI 1.05–15.50), and being hospitalized
for longer periods (OR 2.53, 95% CI 1.49–4.28) remained as
risk factors for MRSA carriage. In contrast, having no contact
with animals (OR 0.38, 95% CI 0.18–0.83) decreased the risk of
MRSA carriage (see Supplementary material, Table S3).
Antimicrobial resistance
Among the 454 S. aureus isolates, we observed resistance to
penicillin (98.5%), trimethoprim-sulfamethoxazole (45.2%),
rifampin (35.7%), cefoxitin (35.7%), tetracycline (17.2%),
erythromycin (12.1%), gentamicin (9.7%), ciproﬂoxacin (8.6%),
chloramphenicol (4.6%), mupirocin (4.2%), clindamycin (4.0%)
and fusidic acid (1.8%). However, besides resistance to
β-lactams, we found signiﬁcant differences between countries
(Fig. 1a): (i) in Angola we highlight the very high levels of
resistance to rifampin (77.3%) and trimethoprim-ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 842.e1–842.e10
842.e5 Clinical Microbiology and Infection, Volume 21 Number 9, September 2015 CMIsulfamethoxazole (66.5%); (ii) in São Tomé and Príncipe we
observed not only high levels of resistance to trimethoprim-
sulfamethoxazole (50.9%), but considerable resistance to
tetracycline (26.3%) and erythromycin (21.9%) as well; (iii) in
Cape Verde we found an important prevalence of
erythromycin-resistant isolates (14.2%); and (iv) in East Timor
the isolates were resistant to tetracycline (20.8%) and fusidic
acid (8.3%) only, but the latter showed the highest value
among the four countries. None of the 454 isolates was
resistant to quinupristin-dalfopristin, linezolid, teicoplanin and
vancomycin.
Among the MRSA isolates we emphasize the following
(Fig. 1b): (i) in Angola an extremely high resistance to
trimethoprim-sulfamethoxazole (92.9%) and rifampin (86.6%);
(ii) in São Tomé and Príncipe the resistance to multiple classes
of antimicrobials in addition to β-lactams (trimethoprim-sulfa-
methoxazole 82.8%; erythromycin 72.4%; tetracycline 69%;
ciproﬂoxacin 37.9%; clindamycin 31%); and (iii) in Cape Verde
the resistance to trimethoprim-sulfamethoxazole (66.7%),
erythromycin and fusidic acid (50% each).
Molecular epidemiology
Although the 162 MRSA belonged to 14 different clonal types,
there were three major clones: clones A (n = 85; 52.5%), B
(n = 32; 19.8%) and C (n = 21; 13.0%) with a different distri-
bution between the three Portuguese-speaking African coun-
tries (Table 1). In Angola, clone A (PFGE A-ST5-SCCmecIVa-
agrII, mainly associated with spa type t105) included most of the
isolates (65.4%), followed by clone B (PFGE B-ST88-IVa-agrIII,
mainly associated with spa type t786) represented by 15.0% ofTABLE 1. Genotypic properties of methicillin-resistant Staphylococ
Cape Verde
Country CC ST spa typesa
Angola (n = 127) 5 5 t105/ t311/ t11657
88 88 t186/ t325/ t786/ t1951/ t3869
8 8 t064/ t104/ t1771
72 72 t3092
72 72 t148
7 789 t091
5 5/2629 t6065
30 30 t6278
22 22 t005
8 8 t1476
São Tomé & Príncipe (n = 29) 5 5 t105/ t14047
88 88 t186/ t786/ t1814
8 8 t064/ t451
1 1 t590
5 105 t002
Cape Verde (n = 6) 88 88 t186/ t12827
8 8 t121
5 5 t002
Clonal complexes (CC) were deﬁned using the eBURST algorithm (assessed on 23 April 2015
founder or subfounder, inside each clonal group); ST, sequence type deﬁned by multilocus s
element.
aMajor spa types are displayed in bold.
bPercentage relative to the total number of methicillin-resistant Staphylococcus aureus in each
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectthe isolates. In São Tomé and Príncipe, clone C (PFGE C-ST8-
IV/V-agrI, mainly associated with spa type t451) was the major
clone (44.8%) followed by clone B (37.9%). In Cape Verde, half
(n = 3) of the MRSA isolates belonged to PFGE ABB-t002-ST5-
VI-agrII. Interestingly, there was a higher diversity of the
SCCmec types and subtypes in clone C-ST8 and of the spa types
associated with clone B-ST88 (Table 1).
The 292 MSSA were distributed over 30 different clonal
types, of which three were prevalent (Table 2): clone K
(20.2%)—PFGE type K-ST15-agrII, mainly associated with spa
type t084; clone L (17.8%)—PFGE type L-ST508-agrI, mainly
associated with spa type t861; and clone M (16.1%)—PFGE
type M-ST152-agrI, mainly associated with spa type t355. All
three clones were predominant in the four countries, with the
exception of clone M-ST152, which was a minor clone in
Angola.
Exotoxins
The presence of genes encoding leukocidins, haemolysins,
exfoliative toxins and enterotoxins is shown in Table 3. Among
the whole collection, 91.5% of the isolates (85.2% of the MRSA
and 94.2% of the MSSA) harboured at least one exotoxin gene.
Leukocidin DE and γ-variant haemolysin were the most
frequent exotoxins in the whole collection, in particular among
MRSA isolates (83.3% and 82.7%, respectively), whereas leu-
kocidin M and exfoliative toxins B and D were absent or rare
among the 454 isolates (0%, 0.2% and 1.5%, respectively) and
were not detected at all among MRSA.
PVL was found in 95 isolates (20.9%) but its prevalence
varied considerably between countries: 6.9% in Angola, 28.3%cus aureus isolates from Angola, São Tomé and Príncipe, and
SCCmec PFGE agr No. of isolatesb PVL+ ACME+
IVa A II 83 (65.4%)
IVa B III 19 (15.0%)
IVc/IVd/V C I 8 (6.3%)
V D I 4 (3.2%)
V E I 1 (0.8%)
V J I 1 (0.8%)
V U II 2 (1.6%)
V X III 2 (1.6%) 1
IVc AN I 1 (0.8%) 1
VII AQ I 6 (4.8%)
IVa A II 2 (6.9%)
IVa B III 11 (37.9%)
IVg/V C I 13 (44.8%)
V H III 2 (6.9%) 2
II ABA II 1 (3.4%)
IVa B III 2 (33.3%)
IVa N I 1 (16.7%) 1
VI ABB II 3 (50.0%)
) and restricted to single locus variant (SLV) and double locus variant from each group
equence typing; PVL, Panton–Valentine leukocidin; ACME, arginine catabolic mobile
country.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 842.e1–842.e10
TABLE 2. Genotypic properties of methicillin-susceptible Staphylococcus aureus isolates from Angola, São Tomé and Príncipe,
Cape Verde and East-Timor
Country CC ST spa typesa PFGE agr No. of isolatesb PVL+
Angola (n = 76) 5 5 t002/ t1215/ t6071/ t9921 A II 4 (5.3%) 1
8 8 t064 C I 1 (1.3%)
72 72 t148/ t1346 E I 5 (6.6%)
15 15 t084/ t346/ t774 K II 9 (11.8%) 1
45 508 t050/ t095/ t861/ t1574/
t1346/ t2626/ t12218
L I 18 (23.7%)
152 152 t355 M I 4 (5.3%) 2
8 8 t008/ t1476 N I 2 (2.6%)
121 121 t314/ t1077 O IV 3 (4.0%) 1
707 2367 t1458/ t12259 P III 3 (4.0%)
45 45 t939/ t11656 Q IV 9 (11.9%)
1 1 t127/ t693 R III 2 (2.6%)
25 25 t349/ t1350/ t6205 W I 5 (6.6%) 4
30 30 t1202/ t9118 X III 7 (9.2%) 3
672 672 t12219 AA I 1 (1.3%)
Singleton 601 t957 AF II 1 (1.3%)
Singleton 2728 t5187 AG III 1 (1.3%)
5 2229 t1476 AK I 1 (1.3%)
São Tomé & Príncipe (n = 85) 5 5 t311/ t319/ t14190 A II 3 (3.5%) 1
88 88 t4195 B III 1 (1.2%)
8 8 t064/ t1774/ t13119 C I 4 (4.7%)
72 72/2448 t148/ t324/ t11082 E I 3 (3.5%)
97 97 t521 G I 1 (1.2%)
15 15 t084 K II 29 (34.1%) 19
45 508/2446 t635/ t861/ t2771/ t5602/
t10763
L I 13 (15.3%)
152 152 t355/ t1299/ t9564 M I 12 (14.1%) 12
121 121 t159/ t2304 O IV 6 (7.1%) 6
707 2367 t1458 P III 1 (1.2%)
45 45/2447 t939/ t14189 Q na 4 (4.7%)
1 1 t1931 R III 1 (1.2%)
25 25 t078 W I 1 (1.2%) 1
30 3161 t017 X III 1 (1.2%)
5 6 t701 Z I 2 (2.4%)
718 718 t11083 AC II 1 (1.2%)
8 94 t008 AD I 1 (1.2%)
80 80 t934 AJ III 1 (1.2%) 1
Cape Verde (n = 107) 5 5 t002 A II 8 (7.5%) 1
72 72 t148/ t3169 E I 6 (5.6%)
97 669 t2734 F I 1 (0.9%)
97 97 t267/ t521 G I 4 (3.7%)
15 15 t084/ t3262 K II 16 (15.0%) 2
45 508 t589/ t861/ t1510/ t2771/
t3216/ t12615/ t12826
L I 16 (15.0%)
152 152 t355/ t774/ t1172 M I 27 (25.2%) 22
121 121 t314 O IV 1 (0.9%) 1
45 45 t939 Q na 3 (2.8%) 1
1 1 t127 R III 6 (5.6%) 2
22 22 t223/ t4640/ t5146/ t8934 T I 8 (7.5%)
1 188 t189 V I 3 (2.8%)
25 25 t078 W I 1 (0.9%)
30 1472 t318/ t12808/ t12828 X III 5 (4.7%) 2
5 6 t701 Z I 1 (0.9%)
398 398 t571 AL I 1 (0.9%)
East Timor (n = 24) 5 5 t105 A II 1 (4.2%) 1
7 7 t091 J I 1 (4.2%)
1 15 t084/ t335 K II 5 (20.8%) 3
45 508 t050/ t13455 L I 5 (20.8%)
152 1633 t355 M I 4 (16.7%) 3
121 2782 t159 O IV 1 (4.2%)
1 1 t127 R III 2 (8.3%)
1 2784 t189 V I 3 (12.5%)
398 2783 t13181 Y I 1 (4.2%)
2483 SLV2483c NT AH na 1 (4.2%)
Clonal complexes (CC) were deﬁned using the eBURST algorithm (assessed on 23 April 2015) and restricted to single locus variant (SLV) and double locus variant from each group
founder or subfounder, inside each clonal group); ST, sequence type deﬁned by multilocus sequence typing; PVL, Panton–Valentine leukocidin; NT, non-typeable.; na, no
ampliﬁcation.
aMajor spa types are displayed in bold.
bPercentage relatively to the total number of methicillin-susceptible Staphylococcus aureus in each country.
cAllelic proﬁle 151-NA-215-34-175-180-169.
CMI Conceição et al. Staphylococcus aureus in former Portuguese colonies 842.e6in Cape Verde, 29.2% in East Timor and 36.8% in São Tomé and
Príncipe (Table 3).
Only ﬁve MRSA harboured PVL and belonged to four
different clonal types (Table 1). The single MRSA isolate relatedClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infto clone USA300 (PFGE N-t121-ST8-IVa-agrI) was conﬁrmed
to be PVL and arginine catabolic mobile element positive.
PVL was detected in 90 MSSA isolates (30.8%) and was found
in isolates belonging to nine different clones (Table 2).ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 842.e1–842.e10
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Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectDiscussionTo our knowledge, this is the ﬁrst global survey of S. aureus
colonization in four former Portuguese colonies, including
Angola, São Tomé and Príncipe, Cape Verde and East Timor.
Although several efforts were made to include isolates from
Mozambique, the institutional review board never approved the
study. For a different reason (war) we were not able to include
Guinea Bissau. Signiﬁcant differences in the MRSA rates were
identiﬁed in the four countries that participated in the study. A
very high MRSA prevalence was reported in Angola (61.6%)
contrasting with a low prevalence in Cape Verde and complete
absence in both hospitals in East Timor. In a study performed in
1997 in Cape Verde [8] we found no MRSA among nasal
samples recovered from the same hospitals screened in this
study, and therefore this is the ﬁrst report of MRSA in this
African archipelago. The different rates of MRSA seem to be in
agreement with the antibiotic availability and usage in each
country.
In our population, being a non-smoker was a relatively high
risk factor for MRSA colonization, which is in agreement with a
previous study from Taiwan [23]. Moreover, we found that the
risk of being an MRSA carrier was higher among younger
people (<18 years old) and in individuals previously submitted
to surgery or in hospital for longer periods (>30 days). A recent
cross-sectional survey of S. aureus nasal carriage in Gabonese
Babongo Pygmies reported an age-related carriage pattern with
a peak colonization of 53.9% in participants between 10 and 20
years of age and a decreasing prevalence in subsequent age
groups [24]. In a healthy Chinese population, young age (24
years old) was shown to be a risk factor for S. aureus nasal
carriage [25]. Young age as a risk factor for MRSA should be
interpreted with caution as high S. aureus nasal colonization
rates in Africa are higher immediately after birth and in teen-
agers [26]. Although HIV infection and administration of mul-
tiple antibiotics were identiﬁed as risk factors for S. aureus and
MRSA colonization [27], this was not the case in our study. By
contrast, we observed that having no contact with animals
seemed to decrease the risk of carrying MRSA. Isolates of
MRSA belonging to clones ST5-IV and ST88-IV have already
been described in African livestock, in Senegal [28].
Another important clinically relevant ﬁnding from this sur-
veillance study was the baseline information concerning S. aureus
antimicrobial susceptibility in former Portuguese colonies that
we were able to obtain. These data are of major importance as a
guide for implementation of adequate empiric therapies for
S. aureus infections and to prevent treatment failures in the
absence of information on antibiotic susceptibility testing. We
described a global resistance to trimethoprim-sulfamethoxazoleious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 842.e1–842.e10
CMI Conceição et al. Staphylococcus aureus in former Portuguese colonies 842.e8in the three African countries. Prophylactic use of
trimethoprim-sulfamethoxazole in resource-constrained areas
is widely recommended for HIV-infected or HIV-exposed chil-
dren, for everyone with CD4 cell counts below 350, and for
those with stage III and IV disease [29]. Moreover,
trimethoprim-sulfamethoxazole is inexpensive, orally adminis-
tered and usually available without prescription in these coun-
tries and therefore widely used. Resistance to trimethoprim-
sulfamethoxazole confers cross-resistance to sulfadoxine/pyri-
methamine, which is used to treat malaria, so it may pose an
additional concern in these countries besides its limited utility as
an anti-staphylococcal agent. We also found an extremely high
preponderance of rifampin-resistant S. aureus in Angola, which
may be explained by the important prevalence of tuberculosis in
the country [30] and subsequent widespread use of rifampin as
the ﬁrst therapeutic option in the treatment of this disease.
Also, MRSA isolates from São Tomé and Príncipe showed
resistance to multiple classes of antimicrobials (erythromycin,
tetracycline, ciproﬂoxacin and clindamycin) in addition to
resistance to β-lactams and trimethoprim-sulfamethoxazole.
Antibiotic availability in São Tomé and Príncipe is ﬂuctuates
greatly and prescription is mainly dependent on the antibiotics
that are available at the time of prescribing, resulting in selective
pressure on different classes of antimicrobial agents.
In East Timor the isolates were almost exclusively resistant
to penicillin and tetracycline. The wide clinical application of
tetracycline, ease of administration and low price makes it an
antibiotic of choice in low-income countries.
Molecular analysis showed that the clonal distribution of
MRSA differed in the three Portuguese-speaking African
countries (PALOP). Of great interest was the massive preva-
lence of PFGE A-ST5-IVa in Angolan hospitals. ST5-IVa has been
described for the ﬁrst time as the major clone in a paediatric
hospital in Portugal [31]. Although currently it is not a major
clone in Portuguese hospitals, ST5-IVa was recently described
in 19.4% of elderly living in retirement homes [32]. Portugal,
which shows one of the highest rates of MRSA in Europe [4],
has close demographic relationships with Angola. Although a
recent review suggested that the African ST5-MRSA evolved in
Africa from ST5-MSSA through acquisition of the SCCmec
element [33], MRSA dissemination between Portugal and
Angola should not be excluded. However, the major clones
presently circulating in Portugal [34,35], i.e. EMRSA-15 (ST22-
IVh) and the New York/Japan related clone (ST105-II) were
exclusively represented by single isolates in the present study.
As ST5-MRSA is currently widespread in Central and West
Africa, dissemination within the continent is probably the major
reason for the high prevalence of this clone in Angola.
PFGE B-ST88-IVa was the second major clone in the three
PALOP countries. Although ST88-IV has been only sporadicallyClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infreported around the world, with the exception of China where
the prevalence rates reached 16% [36], it was described as
predominant in West, Central and East Africa and so already
deserved the suggestion of using the name of ‘African clone’ to
describe ST88-IV [26,33].
PFGE C-ST8-IV/V was the major clone in São Tomé and
Príncipe and the third most prevalent in Angola. However,
among ST8 MRSA isolates, there was only one closely related
to the highly virulent community-acquired MRSA clone
USA300 (ST8-IVa, PVL-positive, arginine catabolic mobile
element-positive), curiously found among the few MRSA iso-
lates in Cape Verde. So far USA300 MRSA has only been
described among sporadic isolates in the African continent,
namely in Central Africa [37], Gabon [38] and Ghana [39].
Three MSSA clones—ST15, ST508 and ST152—were
dominant in all four former Portuguese colonies. The back-
grounds of the major MRSA clones in PALOP countries were
not coincident with the major MSSA clones, which supports
MRSA clonal dissemination rather than acquisition of the
SCCmec element.
Although ST15 and ST152 have been previously reported as
prevalent in several countries in West Africa [26], to the best of
our knowledge, this is the ﬁrst report showing a wide preva-
lence of MSSA-ST508 not only in different countries in Africa
but also in a country in Asia. This intercontinental spread might
be related to the exchange of populations between former
Portuguese colonies. More recently ST152 was also described
in Haiti [40] and ST15 is currently the second most frequent
clone among MSSA isolates collected in 25 European countries
[41].
Since we have conducted a previous surveillance study in
1997 in Cape Verde [7], in the same hospitals, we could note the
clonal evolution of the major MSSA clones over time: ST669,
ST683 and ST30 were replaced by ST152, ST15 and ST508.
The analysis of the virulence determinants demonstrated a
considerable proportion of PVL-positive isolates, namely among
MSSA (30.8%), which is in agreement with other studies
reporting Africa as an endemic region for PVL-positive S. aureus
[7,9,39,42,43]. The high prevalence of PVL in the African
continent is unexplained, but might be due to alterations in PVL
targets of the host (C5a receptors) [26,44]. Interestingly, the
total proportion of PVL-positive isolates in Angola was low
(6.9%), compared with the remaining countries, namely São
Tomé and Príncipe (36.8%). It has been suggested that the
acquisition of antibiotic resistance in S. aureus involves changes
in virulence factor secretion due to the ﬁtness cost associated
with the expression of resistance, which is reﬂected in
decreased toxin expression [45,46], and could explain the low
prevalence of PVL in Angola, a country that shows higher
antimicrobial resistance levels.ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 842.e1–842.e10
842.e9 Clinical Microbiology and Infection, Volume 21 Number 9, September 2015 CMIIn conclusion, this study provided the ﬁrst comprehensive
overview of the prevalence of MRSA, antibiotic resistance,
virulence content and genetic diversity of the S. aureus popu-
lation in former Portuguese colonies in Africa and the Far East.
The PALOP nations and East Timor now possess factual data
that would help to deﬁne public heath priorities. Angola
showed an extremely high prevalence of MRSA contrasting
with Cape Verde and East Timor. Although the main MRSA
lineages differed between countries, three MSSA clones were
present in all the studied geographic sites. The high levels of
antimicrobial resistance or virulence content warrant
continued surveillance and antimicrobial stewardship pro-
grammes to promote judicious use of antimicrobials in these
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